Pharmaceutical compositions and formulations are provided herein comprising a phosphodiesterase type 5 inhibitor, such as sildenafil citrate and, an adenosine receptor (A1, A2A, A2B, and A3 receptors) antagonist, such as caffeine, for (i) treating erectile dysfunction while (ii) inhibiting the lower of the blood pressure, (iii) increasing the bioavailability of the compositions, and (iv) reducing the Tmax in the subject. Methods of making and administering oral disintegrating tablets are also provided.
